Biography

• Prof. Chen is engaged in the study of pathogenesis and treatment of leukemia. She initiated Leukemia Genomic Anatomy Project and has obtained a series of novel molecular biomarkers and targets for disease classification, prognosis and targeted therapy. She led the team to innovate the synergistic targeted therapy for acute promyelocytic leukemia(APL) with all-trans retinoic acid and arsenic trioxide, and has turned APL from a fatal malignancy to a curable disease, which has been extended to other types of leukemia. Recently, the exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen (LCAR-B38M) in relapsed/refractory multiple myeloma led by her has achieved significant effects. The above research work has profoundly promoted the development of hematology in China and exerted a considerable influence in international medical communities.

Publications

1. Zhang XX, Zhang WH, Chen SJ. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399(10340):2011-2012.

2. Zhang XN, Tan Y, Ling Y, Lu G, Liu F, Yi ZG, Jia XG, Wu M, Shi BS, Xu SB, Chen J, Wang W, Chen B, Jiang L, Yu ST, Lu J, Wang JZ, Xu MZ, Yuan ZH, Zhang Q, Zhang XX, Zhao GP, Wang SY, Chen SJ, Lu HZ. Viral and Host Factors Related to the Clinical Outcome of COVID-19. Nature. 2020;583(7816):437-440.

3. Chen Z, Chen SJ. Poisoning the Devil. Cell. 2017;168(4):556-560.

4. Zhang XW, Yan XJ, Yang FF, Zhou ZR, Wu ZY, Sun HB, Liang WX, Song AX, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z. Arsenic trioxide controls the fate of the PML-RAR oncoprotein by directly binding PML. Science 2010; 328: 240-243.

5. Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, Zhang X, Xu B, Qian WB, Tao R, Yan F, Hu JD, Hou M, Ma XJ, Wang X, Liu YH, Zhu ZM, Huang XB, Liu L, Wu CY, Huang L, Shen YF, Huang RB, Xu JY, Wang C, Wu DP, Yu L, Li JF, Xu PP, Wang L, Huang JY, Chen SJ, Zhao WL. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell.2020;37:403-419.

6. Chen S, Wu JL, Liang Y, Tang YG, Song HX, Wu LL, Xing YF, Yan N, Li YT, Wang ZY, Xiao SJ, Lu X, Chen SJ, Lu M. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell.2021;39(2):225-239.

7. Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu CP, Dong Y, Huang JY, Wang L, Shen Y, Meng GY, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZH, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nature Genetics 2015; 47:1061-1066.

8. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics 2011; 43:309-315.

9. Sun XJ, Chen SJ, Chen Z. Treating leukemia: differentiation therapy for mIDH2 AML. Cell Res. 2019;29:427-428.

10. Lin XJ, Qiao N, Shen Y, Fang H, Xue Q, Cui BW, Chen L, Zhu HM, Zhang SJ, Chen Y, Jiang L, Wang SY, Li JM, Wang BS, Chen B, Chen Z, Chen SJ. Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia. Clin Cancer Res.2021. doi: 10.1158

11. Wang DW, Shao XH, Wang Q, Pan XH, Dai YJ, Yao SX, Yin T, Wang ZG, Zhu J, Xi XD, Chen Z, Chen SJ, Zhang GW. Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. Clin Transl Med. 2021;11(3):e375.

12. Wang Q, Zhang L, Zhang GW, Mao JH, Xi XD, Jiang L, Lv G, Lu J, Shen Y, Chen Z, Zhu J, Chen SJ. Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion. Proc Natl Acad Sci U S A.2021;118(42): e2110887118.

13. Chen L, Zhu HM, Li Y, Liu QF, Hu Y, Zhou JF, Jin J, Hu JD, Liu T, Wu DP, Chen JP, Lai YR, Wang JX, Li J, Li JY, Du X, Wang X, Yang MZ, Yan JS, Ouyang GF, Liu L, Hou M, Huang XJ, Yan XJ, Xu D, Li WM, Li DJ, Lou YJ, Wu ZJ, Niu T, Wang Y, Li XY, You JH, Zhao HJ, Chen Y, Shen Y, Chen QS, Chen Y, Li J, Wang BS, Zhao WL, Mi JQ, Wang KK, Hu J, Chen Z, Chen SJ, Li JM. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proc Natl Acad Sci U S A.2021;118(6):e2020382118.

14. Jiang L, Li XP, Dai YT, Chen B, Weng XQ, Xiong SM, Zhang M, Huang JY, Chen Z, Chen SJ. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome. Proc Natl Acad Sci U S A.2020;117(33):20117-20126.

15. Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, Wu J, Wang Y, Wang J, Yan H, Xu WB, Jiang H, Du J, Ding XY, Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF, Hou J, Li JY, Mi JQ, Chen SJ. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A.2019;116:9543-9551.